SELLAS Life Sciences Group, Inc. Stock

$2.03

9.73% yesterday

Nasdaq, Jun 26, 10:16 pm CET

ISIN

US81642T1007

Symbol

SLS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

SELLAS Life Sciences Group, Inc. Stock price

$2.03

-1.25 38.11% 5Y

Nasdaq, Closing price Thu, Jun 26 2025

+0.18 9.73%

ISIN

US81642T1007

Symbol

SLS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$202.6m

Enterprise Value

$174.2m

Net debt

$-28.4m

Cash

$28.4m

Shares outstanding

90.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

6.65

Financial Health

Equity Ratio

48.71%

Return on Equity

-327.52%

ROCE

-99.50%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

- | -

EBIT

$-27.9m

Net Income

$-27.1m | $-34.4m

Free Cash Flow

$-33.5m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

- | -

EBIT

22.92%

Net Income

24.26% | -11.06%

Free Cash Flow

-10.54%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-0.30

FCF per Share

$-0.37

Short interest

19.14%

Employees

15.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Get Started for Free Today

SELLAS Life Sciences Group, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from SELLAS Life Sciences Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	11 11	25% 25% -
- Research and Development Expense	17 17	22% 22% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-28 -28	23% 23% -
Net Profit	-27 -27	24% 24% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

SELLAS Life Sciences Group, Inc. Stock News

Neutral

GlobeNewsWire

●

22 days ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year

Neutral

GlobeNewsWire

●

25 days ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company foc...

Neutral

GlobeNewsWire

●

about one month ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the A.G.P. ...

More SELLAS Life Sciences Group, Inc. News

Company Profile

SELLAS Life Sciences Group, Inc. engages in the development and commercialization of immunotherapeutics for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Head office	United States
CEO	Angelos Stergiou
Employees	15
Founded	2006
Website	www.sellaslifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now